Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine by Brandt, K. et al.
 
Case Rep Oncol 2010;3:349–353 
DOI: 10.1159/000321367 
Published online: 
October 4, 2010 
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only. 
 
Kalina Brandt    University Hospital Carl Gustav Carus, Department of Internal Medicine I 
Technical University of Dresden, Fetscherstrasse 74, DE–01307 Dresden (Germany) 
Tel. +49 3514 587 117, Fax +49 3514 587 220 
E-Mail Kalina.Brandt @ uniklinikum-dresden.de 
 
349
   
Auricular Oedema and 
Dyshidrotic Eczema in a Patient 
with Acute Myeloid Leukaemia 
Treated with Cytarabine 
K. Brandta    K. Schäkelb    F. Stölzela    J. Janscheka    
G. Ehningera    M. Schaicha 
aUniversity Hospital Carl Gustav Carus, Department of Internal Medicine I, 
Technical University of Dresden, Dresden, and bDepartment of Dermatology, 
Heidelberg University Hospital, Heidelberg, Germany 
 
Key Words 
Cutaneous toxicity · Cytarabine · Auricular oedema · Palmar dyshidrotic eczema · Acute 
myeloid leukaemia 
 
Abstract 
Cytarabine is an effective drug in the treatment of haematological malignancies. The 
therapy is associated with various complications. Frequencies of dermatological side-
effects range from 2–72% and occur most commonly after high-dose regimens. Although 
most cutaneous reactions are mild and resolve spontaneously within several days, they 
may result in an increased risk of infection and alterations in comfort. In some cases, 
severe life-threatening reactions have been reported. Here we describe the case of a 
patient with acute myeloid leukaemia, who developed severe exceptional skin toxicity in 
terms of auricular oedema and palmar dyshidrotic eczema after the application of low-
dose cytarabine. Re-administration of the drug resulted in reduced skin toxicity during 
further cycles of chemotherapy. Negative epicutaneous patch-testing supported the 
existence of cytarabine-provoked toxicity. 
 
Introduction 
Cytarabine is a pyrimidine antagonist used in the treatment of haematological 
malignancies. In combination with other chemotherapeutic agents, it is indicated 
amongst others for remission induction in acute myeloid leukaemia (AML). High-dose 
cytarabine is applied in consolidation chemotherapy. Nevertheless, cytarabine is known 
to provoke various adverse effects, including bone marrow depression, fever, nausea, 
vomiting, keratoconjunctivitis, liver-function abnormalities, pulmonary, gastrointestinal 
and neurological complications and skin reactions. Especially in high-dose regimens,  
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dermatological side-effects of cytarabine therapy occur more prevalently. The frequencies 
of toxic skin events range from 2–72% in the literature [1]. Here we report the case of a 
patient with AML, who developed exceptional skin toxicity in terms of auricular oedema 
and palmar dyshidrotic eczema. 
Case Report 
A 38-year-old woman was admitted to our hospital because of recurrent syncopes, haematomas and 
hypermenorrhea for further investigations. At presentation, full blood count demonstrated a 
leukocytosis of 50.6 × 10
9/l, anaemia of 7.41 g/dl (4.6 mM) and a platelet count of 17 × 10
9/l. Seventy-one 
percent blast cells were noted on the peripheral blood smear. Bone marrow examination established the 
diagnosis of AML with maturation according to the WHO classification and aberrant expression of 
CD7. Cytogenetic analysis revealed mosaicism for trisomy 19 (46,XX/47,XX+19). Molecular biology 
remained negative for mutations in the FLT3 and NPM1 genes. The patient was included into the 
prospective multicentre trial AML2003 of the Study Alliance Leukemia (SAL). Induction chemotherapy 
consisted of daunorubicin 60 mg/m
2 (days 3–5) and cytarabine 100 mg/m
2 (days 1–7). In addition to 
chemotherapy, the patient received supportive medication consisting of levofloxacin 500 mg per day 
(q.d.) on days –3 to 1, posaconazole 600 mg q.d. on days –3 to 6, acyclovir 600 mg q.d. on days –3 to 6, 
allopurinol 300 mg q.d. on days –3 to 6, heparin 10,000 IU q.d. on days 5–6 and esomeprazole 20 mg 
q.d. on days –3 to 6. On day 1 of the induction therapy, the patient developed fever and was set on 
piperacillin-tazobactam 13.5 g q.d. on days 1–6. Due to hypermenorrhea, methylergometrine 0.75 mg 
q.d. was given on days –2 to 6. Before starting chemotherapy, hydroxycarbamide 3 g q.d. was given on 
days –3 to –1 because of hyperleukocytosis. On day 6 of the first induction therapy, the patient 
developed a doughy, painful erythematous swelling of both ears (fig. 1a), haemorrhagic papulovesicles 
on both hands and an erythematous patch on the thenar eminence accompanied by pyrexia (fig. 1b). 
The clinical picture of both ears was evocative of the immune-mediated relapsing polychondritis 
(polychondritis recidivans et atrophicans). 
However, first induction chemotherapy was completed. Because of a potential allergic cause of the 
described reactions, the supportive medication mentioned above was stopped on day 6. Due to 
increasing body temperature and leukopenia (1.66 × 10
9/l) piperacilline-tazobactam was replaced by the 
antibiotic combination of vancomycin and meropenem on day 7. Dermatological manifestations were 
treated with topical and oral administration of glucocorticoids and regressed within 7 days (fig. 2a, b). 
For response evaluation, the patient underwent bone marrow examination on day 14 after the start 
of the first induction therapy. Morphological and immunophenotyping analyses showed a good 
response with 4% blast cells in the hypocellular bone marrow. According to the study protocol, second 
induction therapy was initialised on day 22. Dosages and chronological administration of the 
chemotherapeutic drugs daunorubicin and cytarabine were consistent with the first induction therapy. 
Between the chemotherapy cycles, antiviral, antimycotic and antibiotic therapy with acyclovir, 
posaconazole and levofloxacin was given again and did not provoke any dermatological side-effects. 
Prophylactic medication of heparin and esomeprazole was also started again. On the first day of the 
second induction therapy, pyrexia recurred, probably in the context of an adverse event of cytarabine. 
Even so, antibiotic therapy with levofloxacin was again replaced by piperacillin-tazobactam on day 2 of 
the second induction therapy because of persistent neutropenia. On day 3, the patient developed a 
maculopapular exanthema of the neck, lower legs and thenar eminence of the left hand as well as 
auricular erythematous swelling on both sides. However, compared to the initial dermatological 
manifestation during the first induction chemotherapy, the degree of skin toxicity was markedly 
reduced. Therapy consisted of topical and oral glucocorticoids, again. Efflorescences dissolved within 4 
days. 
Based on standard-risk AML, the patient underwent three consolidation chemotherapy cycles with 
high-dose cytarabine (2 × 3 g/m
2 on days 1, 3 and 5), consistent with the study protocol. A HLA-
matched sibling donor for allogeneic hematopoietic stem cell transplantation was not available. A 
pronounced reduction of dermatological toxicity appeared on day 7 of the first and second 
consolidation chemotherapy, demonstrating as maculopapular exanthema of the lower legs. No 
dermatological toxicity was observed after application of the third consolidation therapy. 
Supplementary medication did not differ from treatment during both induction regimens.   
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Epicutaneous patch-testing with cytarabine was performed before starting the third consolidation 
chemotherapy. 24, 48 and 72 h after administration of the drug, no cutaneous reaction could be 
observed, which argues against the possibility of cytarabine-specific and T-cell mediated type IV 
reactions in this patient. 
Discussion 
As cyrarabine is considered one of the most important drugs for the treatment of 
AML, it is important to be aware of complications that may occur in patients treated with 
this drug. There are several reports in the literature that mention cytarabine as a cause of 
severe dermatological toxicity [1, 2]. Nevertheless, mild skin complications preponderate. 
Most of the cutaneous reactions begin few days after the initiation of chemotherapy and 
resolve within several days of their appearance. Known manifestations of skin toxicity can 
be multifaceted, ranging from palmar-plantar erythema and morbilliform eruptions on 
the trunk to erythematous urticarial plaques, bullous erythema and painfull swelling. Two 
cases of toxic epidermal necrolysis had been described after the use of high-dose 
cytarabine [2, 3]. Skin changes are supposed to be dose-related and occur more frequently 
with high-dose regimens [1]. Regarding intensity of dermatological adverse reactions 
after repetitive administration of cytarabine, gradual amelioration of symptoms during 
further cycles of chemotherapy is not uncommon [1, 4, 5]. The pathogenesis of 
cytarabine-induced dermatological toxicity still remains unclear. 
Here, we report the unusual case of distinctive auricular swelling, accompanied by 
palmar papulovesicles as a variant of cytarabine-induced toxicity. Skin manifestation 
occurred several days after the administration of cytarabine and showed diminished 
intensity in the course of drug re-administration. Although skin toxicity induced by low-
dose cytarabine is reported to be rare, the patient developed severe dermatological 
complications after the first cycle. Negative epicutaneous patch-testing was used to rule 
out specific T-cell mediated responses and supports the existence of cytarabine-provoked 
toxicity. Finally, a connection between supportive medication and cutaneous reaction 
seems improbable. For the most part, co-medication was given non-intermittent during 
the cycles. However, skin toxicity recurred several times. Moreover, there is no evident 
chronological relationship between dermatological manifestation and supportive drug 
administration. 
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Fig. 1. a Erythematous, doughy swelling of both ears on day 6 of the first induction therapy (right side). 
b Haemorrhagic papulovesicles on both hands and erythematous patch on the thenar eminence on day 
6 of the first induction therapy. 
 
 
 
Fig. 2. a, b Complete restitution of cutaneous toxicities 7 days after their appearance. 
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